GlassScriptPhysician profile
Nilesh V Patel
NPI 1053397562
$6,943.20
in general payments reported to CMS, 2019-2025
37 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $130 · 2021: $168 · 2022: $598 · 2023: $2,290 · 2024: $1,243 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591 · Travel and Lodging: $1,654 · Consulting Fee: $19.22 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,590.67 |
| Travel and Lodging | $1,654.29 |
| Consulting Fee | $19.22 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,725.83 | 2023-2024 | Single Use Suction Valve (Sterile), Olympus |
| Glaxosmithkline, LLC. | $742.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $634.10 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $494.23 | 2019-2025 | Dupixent |
| Amgen INC. | $316.21 | 2019-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $272.18 | 2021-2025 | |
| Grifols USA, LLC | $263.36 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.66 | 2019-2025 | Jascayd, Ofev, Spiriva Respimat |
| United Therapeutics Corporation | $226.45 | 2021-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $224.64 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $181.21 | 2019-2024 | Yupelri |
| Philips North America LLC | $166.51 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Baxter Healthcare | $162.96 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $129.00 | 2019-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $125.74 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $115.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $115.16 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $102.89 | 2020-2025 | Glassia, Cuvitru |
| Genentech USA, INC. | $81.82 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $81.22 | 2019-2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $76.58 | 2025 | Wegovy, Rybelsus, Ozempic |
| Electromed, INC. | $52.33 | 2022-2023 | Smartvest |
| Shire North American Group INC | $47.76 | 2019 | |
| Mallinckrodt Hospital Products INC. | $47.51 | 2022-2025 | Acthar |
| Viatris Specialty LLC | $44.79 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $41.52 | 2025 | Inspire |
| Ani Pharmaceuticals, INC. | $38.61 | 2022-2024 | Purified Cortrophin Gel |
| Circassia INC. | $31.04 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $31.03 | 2023-2024 | Giapreza |
| Teva Pharmaceuticals USA, INC. | $22.06 | 2023 | |
| Adma Biomanufacturing LLC | $19.22 | 2025 | |
| Vifor Pharma, INC. | $18.95 | 2024 | Veltassa |
| Smith+Nephew, INC. | $18.80 | 2023 | Renasys Go V2 Home |
| Masimo Corporation | $15.41 | 2021 | |
| Lilly USA, LLC | $10.79 | 2019 | |
| Abiomed | $8.57 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.